Experts call for better design of early drug trials for Alzheimer’s and related dementias
Study shows racial differences in personal care product use, may lead to health inequities
18 May 2021Psychosocial support interventions in medical settings can improve survival
18 May 2021Experts call for better design of early drug trials for Alzheimer’s and related dementias
An expert panel convened by the Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) provides guidance on best practices for the design of early drug trials for Alzheimer’s disease, frontotemporal degeneration (FTD), and other neurodegenerative dementias. Their guidance was published in the May 18, 2021 issue of Neurology, the medical journal of the American Academy of Neurology.
